K. Migliaccio-Walle

发表

Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis.

J. Caro, K. Ishak, K. Migliaccio-Walle, 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States

J. Caro, J. Möller, K. Simpson, 2013, PharmacoEconomics.

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients

K. Tolley, K. Migliaccio-Walle, N. Oliver, 2010, Journal of medical economics.

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease

J. Caro, J. O'brien, K. Ishak, 2012, PharmacoEconomics.

BMC Cardiovascular Disorders BioMed Central

J. Caro, I. Proskorovsky, K. Ishak, 2005 .

The Prognostic Significance of Diabetes in Patients Diagnosed With Peripheral Arterial Disease

J. Caro, I. Proskorovsky, K. Ishak, 2007 .

Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.

D. Globe, M. Chancellor, T. Bramley, 2013, Clinical therapeutics.

NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors

J. Caro, D. Getsios, K. Migliaccio-Walle, 2012, PharmacoEconomics.

Anticoagulation Prophylaxis in Orthopedic Surgery: An Efficiency Frontier Approach

T. Simon, D. Rublee, K. Migliaccio-Walle, 2012, Postgraduate medicine.

Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.

J. Caro, J. Speckman, K. Flegel, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

889-3 Estimating life-years lost due to atherothrombotic events: Flexible survival functions for use in disease modeling

J. Caro, W. Weintraub, K. Ishak, 2004 .

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies

J. Silverberg, V. Joish, S. Sullivan, 2022, American Journal of Clinical Dermatology.

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

S. Jagannath, D. Siegel, D. Globe, 2015, American health & drug benefits.

Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events.

J. Caro, J. Caro, K. Migliaccio-Walle, 1999, The American journal of medicine.

Economic considerations for mid-urethral sling procedures among patients with stress urinary incontinence.

T. Bramley, Sanjoy Roy, P. Hinoul, 2013, Journal of long-term effects of medical implants.

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

J. Caro, D. Getsios, J. O'brien, 2003, Clinical therapeutics.

Evaluation of the consequences associated with diffuse vascular disease history in patients diagnosed with peripheral arterial disease: estimates from Saskatchewan health data

M. Stokes, I. Proskorovsky, D. Popovici-Toma, 2010, BMC cardiovascular disorders.

Comparing medications in a therapeutic area using an NNT model.

J. Caro, W. Klittich, K. Ishak, 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

343 Cost-effectiveness of deferasirox in lower-risk myelodysplastic syndrome (MDS) in Canada

K. Migliaccio-Walle, D. Bozkaya, H. Lau, 2011 .

Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.

J. Caro, S. Gottlieb, P. Deedwania, 2005, Journal of cardiac failure.

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

T. Livingston, K. Migliaccio-Walle, D. Bozkaya, 2017, Journal of medical economics.

Economic Impact of the Use of an Absorbable Adhesion Barrier in Preventing Adhesions Following Open Gynecologic Surgeries.

H. Chapa, Sanjoy Roy, M. Weisberg, 2015, Journal of long-term effects of medical implants.

The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada

J. Caro, J. O'brien, I. Proskorovsky, 2006, BMC Health Services Research.

Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial

J. Burke, T. Phillips, M. Fanale, 2023, Leukemia & lymphoma.

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Jaime J Caro, Denis Getsios, J. Caro, 2007, PharmacoEconomics.

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

J. Caro, D. Getsios, J. Ishak, 2003, BMC geriatrics.

MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making

D. Campbell, B. Devine, K. Migliaccio-Walle, 2022, Value in Health.

10-Year Impact on Productivity Costs Associated with Mortality in Stage III or IV Classical Hodgkin Lymphoma Based on the Overall Survival Update of the ECHELON-1 Trial: Application of an Oncology Simulation Model in the United States

J. Burke, T. Phillips, K. Migliaccio-Walle, 2022, Blood.

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

J. Burke, T. Phillips, M. Fanale, 2021, Blood.

Management options for children with attention-deficit/hyperactivity disorder: a regional perspective on value.

S. Pearson, D. Ollendorf, J. Colby, 2013, Journal of comparative effectiveness research.

Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care

J. Caro, D. Getsios, A. Ward, 2001, Neurology.

Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer’s Disease in the Health Care Systems of Different Countries

J. Caro, D. Getsios, A. Ward, 2004, Drugs & aging.

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

Denis Getsios, Alexandra Ward, Jaime Caro, 2002, BMC neurology.

Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.

J. Caro, J. O'brien, G. Raggio, 2001, PharmacoEconomics.

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy

K. Migliaccio-Walle, D. Bozkaya, M. Ahmad, 2020, Journal of managed care & specialty pharmacy.

The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database.

J. Caro, I. Proskorovsky, K. Ishak, 2005 .

The morbidity and mortality following a diagnosis of peripheral arterial disease: Long-term follow-up of a large database

I. Proskorovsky, K. Ishak, K. Migliaccio-Walle, 2005, BMC cardiovascular disorders.